Amer 2006.

Methods	Design: randomised, placebo‐controlled, parallel‐group trial
Participants	Number assigned: 49 children (macrolide n = 25, placebo n = 24) Age in years (mean): macrolide: 8.0, placebo: 8.4 Setting: secondary care
Interventions	Indication: pityriasis rosea Type of macrolide: azithromycin Route: per oral Dose per day: 500 mg (maximum) Duration of treatment: 5 days Total treatment dose: 2500 mg (maximum)
Outcomes	Adverse events stated as an outcome in trial registration/protocol/paper: unclear Adverse events ascertainment: participant asked Adverse events: data reported Antimicrobial resistance: not reported Death: not reported
Funding sources	Study supported by a grant from Pfizer Inc.
Notes	Concomitant medication: unclear
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Sequence generation not described in detail.
Allocation concealment (selection bias)	Unclear risk	Allocation not described.
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Identical‐appearing placebo
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Blinding of both participants and clinicians
Incomplete outcome data (attrition bias) All outcomes	Low risk	No dropout
Selective reporting (reporting bias)	Low risk	Adverse events not clearly stated as an outcome. However, standardised ascertainment of adverse events at each follow‐up visit and adverse events reported.
Other bias	Low risk	None were identified.